Automated estimation of adult left-ventricular ejection fraction from previously acquired transthoracic echocardiography images to assist clinician cardiac evaluation.
Clinical role
Automated quantitative assistance for left-ventricular ejection-fraction assessment.
Images and patients
Ultrasound · Heart/Cardiovascular
Key limitation
The estimate assists cardiac evaluation and does not replace clinician interpretation or other clinical information; performance depends on eligible, adequate-quality echocardiography images.
Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Imaging and anatomyUltrasound · Heart/Cardiovascular
Workflow roleAutomated quantitative assistance for left-ventricular ejection-fraction assessment.
Required inputPreviously acquired adult transthoracic echocardiography images meeting the cleared input and image-quality requirements.
Output and human actionAn automated left-ventricular ejection-fraction estimate for clinician review.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Automated estimation of adult left-ventricular ejection fraction from previously acquired transthoracic echocardiography images to assist clinician cardiac evaluation.
The estimate assists cardiac evaluation and does not replace clinician interpretation or other clinical information; performance depends on eligible, adequate-quality echocardiography images.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
No new performance testing was provided for DEN220063; the packet summarizes prior K210747 testing, including retrospective multicenter validation on 186 patient studies.
Exact FDA submission
Checked 2026-09-19
The exact De Novo summary states that the current submission added a PCCP and summarizes the prior 186-study validation.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
No new performance testing was provided for DEN220063; the packet summarizes prior K210747 testing, including retrospective multicenter validation on 186 patient studies.
FDA source
Exact FDA submission
Checked 2026-09-19
The exact De Novo summary states that the current submission added a PCCP and summarizes the prior 186-study validation.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for DEN220063. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Previously acquired adult transthoracic echocardiography images meeting the cleared input and image-quality requirements.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact De Novo summary establishes processing of previously acquired echocardiography images; current device, PACS, and hosting compatibility requires vendor confirmation.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-08 ·
Returned objects
Source context, not route validation: An automated left-ventricular ejection-fraction estimate for clinician review.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: An automated left-ventricular ejection-fraction estimate for clinician review.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact De Novo summary establishes processing of previously acquired echocardiography images; current device, PACS, and hosting compatibility requires vendor confirmation.
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: GE HealthCare's own press release announces the acquisition of Caption Health, Inc., and Caption AI is sold as a GE HealthCare product (Vscan Air Caption AI page on gehealthcare.com). Corporate program statement; portal content is credentialed; exact-release scope is not established.
The De Novo decision summary states that a qualified medical professional must inspect the data being used for analysis and diagnosis, and ensure that the data is sufficient and appropriate in anatomical correctness and both spatial and temporal resolution.
Exact FDA submission
Checked 2026-10-27
User qualification wording only; the summary specifies no training program or training offering for this device.
GE HealthCare's product security page states that it provides a credentialed Product Security Portal offering security updates, vulnerability status and actions, and patch views for GE HealthCare products under its Cybersecurity Risk Management System, and links its Coordinated Vulnerability Disclosure Statement.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names GE HealthCare generally and does not scope these commitments to any specific product release; exact-release scope is not established. Portal access is credentialed; contents were not read.
GE HealthCare describes the current Caption AI family as combining guided cardiac image acquisition with automated ejection-fraction estimation on supported ultrasound workflows.
product family · checked 2026-09-08
Confirm exact-release availability, interfaces, hosting, security, support, and commercial terms during procurement.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-19Last searched
17Fields reviewed
11Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads
Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA support assessed on 2026-09-19. Packet-supported facts: purpose, modality, anatomy, intendedUsers, input, output, limitations; packet-unavailable facts: evidenceSummary. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, fda decision summary, fda de novo summary, vendor support page, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact DEN220063 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-08 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Authorized purpose: Guides medical professionals acquiring ten standard 2D transthoracic echocardiographic views in adults requiring a cardiac ultrasound examination; acquired images require qualified clinical interpretation.
Ligence Heart is a fully automated software platform that processes, analyses and makes measurements on acquired transthoracic cardiac ultrasound images, automatically producing a full report with measurements of several key cardiac structural and functional parameters. The data produced by this software is intended to be used to support qualified cardiologists or sonographers for clinical decision making. Ligence Heart is indicated for use in adult patients. Ligence Heart has not been validated for the assessment of congenital heart disease, valve disease, pericardial disease, and/or intra-cardiac lesions (e.g., tumors, thrombi). Limitations: Poor image capture will lead to poor annotations and subsequent measurements. Multiple image quality algorithms are used to filter out images of poor quality. Our software complements good patient care and does not exempt the user from the responsibility to provide supervision, clinically review the patient, and make appropriate clinical decisions. If no gender is present, female referenced guideline values will be used for conclusions. If Body Surface Area (BSA) is not present, indexed values cannot be provided. During image acquisition, inappropriate use of the echo machine, use of non-cardiac ultrasound probes, or use of suboptimal settings (e.g., gain, contrast, depth) may lead to lower accuracy of the software. Ligence Heart has not been validated in patients with prosthetic or surgically altered cardiac valves, implantable intracardiac devices, or irregular (non-sinus) rhythm; these conditions may affect automated measurement accuracy.
Authorized purpose: PVAD IQ supports qualified-physician clinical decision support by identifying the aortic annulus and PVAD inlet, calculating their mean distance, and identifying clips acceptable for this measurement.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.